65,437 trials
Rheumatoid Arthritis
Primary: Number of Acute Infusion Reactions in the First 24 Hours After Oral Prednisone Pretreatment to Initial Rituximab Infusion — 50 acute infusion reactions
Non-Hodgkin's Lymphoma · Hodgkin's Disease
Primary: Phase 1: Determination of Maximum Tolerated Dose (MTD) First Without and Then With Administration of Prophylactic G-CSF. — 2; 3; 4; 5 mg/m2
Influenza
Primary: Number of Participants With rtPCR-confirmed Influenza-Like Illness — 96; 138 participants
Anemia, Aplastic
Primary: Disease-free Survival (DFS) — 6; 3; 9; 4 participants
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
Chronic Kidney Disease
Primary: Patient's Quality of Life — 34; 38; 35; 27 % of patients
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST) — 11 percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation — 81.5 percentage of participants
Gastrointestinal Stromal Tumor
Primary: Progression-free Survival (PFS) — 3.9 months
Sensorineural Hearing Loss
Primary: Speech Intelligibility — 63; 60; 59; 48 Percentage of understood word
Helicobacter Infection
Primary: Number of Participants in Each Arm/Group With Successful H. Pylori Eradication — 67; 63; 36 participants
Major Depression
Primary: 17-item Hamilton Depression Rating Scale — 19; 10 units on a scale
Dry Eye Disease
Primary: Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year — 38; 118; 40; 104 participants
Chronic Hepatitis C (CHC)
Primary: Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 85.7; 94.7 percentage…
End Stage Renal Disease
Primary: Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months — 38.3; -3.4 percent difference in geometric mean — p=0.047